Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Change in Cash (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed Change in Cash for 16 consecutive years, with $75.0 million as the latest value for Q4 2025.

  • Quarterly Change in Cash rose 21465.8% to $75.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $126.9 million through Dec 2025, up 3629.82% year-over-year, with the annual reading at $126.9 million for FY2025, 3629.82% up from the prior year.
  • Change in Cash hit $75.0 million in Q4 2025 for Ironwood Pharmaceuticals, up from $47.6 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $84.1 million in Q1 2023 to a low of -$565.5 million in Q2 2023.
  • Historically, Change in Cash has averaged -$7.5 million across 5 years, with a median of $24.7 million in 2024.
  • Biggest five-year swings in Change in Cash: plummeted 535.3% in 2023 and later surged 21465.8% in 2025.
  • Year by year, Change in Cash stood at $45.9 million in 2021, then soared by 78.87% to $82.0 million in 2022, then tumbled by 123.54% to -$19.3 million in 2023, then soared by 101.8% to $348000.0 in 2024, then soared by 21465.8% to $75.0 million in 2025.
  • Business Quant data shows Change in Cash for IRWD at $75.0 million in Q4 2025, $47.6 million in Q3 2025, and -$15.6 million in Q2 2025.